Purpose: Beginning in 1993 at a single chronic fatigue syndrome (CFS) treatment center, we began studies that demonstrate Epstein-Barr virus (EBV) nonpermissive replication.
In the most recent study performed, EBV nonpermissive replication:
• Is the cause of 28.3% of 106 consecutive CFS cases,
• And is etiologic with human cytomegalovirus (HCMV) and/or human herpes virus 6 (HHV-6) as a coinfection in an additional 52.8% of CFS cases.
Therefore EBV is causally involved in 81% of cases of CFS.
Further, EBV CFS is effectively treated with long-term valacyclovir. Coinfection HCMV and HHV-6 CFS requires valganciclovir with valacyclovir.
Patients and Results:
The validated Energy Index Point Score(r) (EIPS(r)) monitors severity of CFS illness and its recovery.
A specific CFS diagnostic panel identifies EBV CFS subsets.
Four separate EBV CFS therapeutic studies of several hundred CFS patients describe valacyclovir administration and long-term patient recovery.
With valacyclovir, serum EBV titers (EBV, early antigen (diffuse); EBV, viral capsid antigen, immunoglobulin M); 24-hour electro- cardiography Holter monitors; and cardiac dynamic studies improve.
Nonpermissive EBV infection is causal in a significant proportion of CFS cases. EBV CFS is safely and effectively treated with long-term valacyclovir.
Source: Virus Adaptation and Treatment, Sep 2010;#2, pp. 135-145. Lerner AM, Beqaj SH, Gill K, Edington J, Fitzgerald JT, Deeter RJ. Department of Medicine, William Beaumont Hospital, Royal Oak, MI; DCL Medical Laboratories, Indianapolis, IN; The Dr A Martin Lerner, Chronic Fatigue Syndrome Foundation, Beverly Hills, MI; Department of Medical Education, University of Michigan Medical School, Ann Arbor, MI; Hematology-Oncology, Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA. [Email: firstname.lastname@example.org]